These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Treatment of chronic obstructive respiratory disease with a new purified theophylline preparation in delayed-action form]. Kaik G Wien Med Wochenschr; 1984 Apr; 134(7):163-9. PubMed ID: 6741156 [TBL] [Abstract][Full Text] [Related]
24. [Tolerance of a new oral long-acting theophylline in patients with obstructive airway diseases]. Nolte D; Dusik B Fortschr Med; 1983 Jul; 101(25):1203-6. PubMed ID: 6884955 [TBL] [Abstract][Full Text] [Related]
25. [Possibilities for optimizing therapy with theophylline preparations. I. On the pharmacokinetics of theophylline preparations]. Wiesner B; Sehrt I; Iwainsky H Z Erkr Atmungsorgane; 1984; 162(1):3-10. PubMed ID: 6719957 [TBL] [Abstract][Full Text] [Related]
26. The tolerability of a new oral controlled release theophylline preparation in patients with obstructive airways diseases. Nolte D; Dusik B Br J Clin Pract Suppl; 1984; 32():18-21. PubMed ID: 6432018 [No Abstract] [Full Text] [Related]
27. [Theophylline therapy in obstructive respiratory diseases. 1. Bioavailability and pharmacokinetics of various theophylline preparations (author's transl)]. Wemhöner S; Oellerich M; Sybrecht G Prax Klin Pneumol; 1981 Jan; 35(1):36-41. PubMed ID: 7208408 [No Abstract] [Full Text] [Related]
28. Combined administration of controlled release theophylline and ranitidine: a 53-day controlled survey in patients with chronic obstructive lung disease (COLD) and peptic disease. Dal Negro R; Turco P; Pomari C; Trevisan F; De Conti F; Cordaro CI Br J Clin Pract; 1987 Nov; 41(11):1004-8. PubMed ID: 3504314 [No Abstract] [Full Text] [Related]
29. [Effect and side effects of a depot theophylline preparation within the scope of a clinical trial]. Wilke A; Weinecke A; Weide W; Schäfer K; Iwainsky H Z Erkr Atmungsorgane; 1986; 167(3):245-53. PubMed ID: 3551350 [TBL] [Abstract][Full Text] [Related]
30. [Optimizing of therapy with theophylline preparations in obstructive respiratory diseases. 4. Effect of theophylline on mucociliary clearance and maximal inspiratory mouth occlusion pressure]. Schmidt G; Ranke C; Creutzig H; Oellerich M; Sybrecht GW Prax Klin Pneumol; 1983 Apr; 37(4):154-60. PubMed ID: 6866926 [No Abstract] [Full Text] [Related]
31. [Use of Unilair in general practice conditions. Treatment of chronic obstructive airway diseases with theophylline]. Gregori P; Hader S; Samiri H; Wiemann M; Yousif MJ; Kiebart M Fortschr Med; 1997 Jan; 115(1-2):54-5. PubMed ID: 9102383 [No Abstract] [Full Text] [Related]
32. [Effect of theophylline-ethylenediamine in obstructive lung disease (author's transl)]. Brossmann D; Ruf G; Wiessmann KJ Dtsch Med Wochenschr; 1980 Mar; 105(12):410-3. PubMed ID: 7363785 [TBL] [Abstract][Full Text] [Related]
33. [The effect of theophylline in slow-release or regular preparations in chronic obstructive lung disease. A double-blind study comparing Nuelin Depot, Nuelin and placebo]. Aamodt T; Lien JT; Haaversen O; Osmundsen K Tidsskr Nor Laegeforen; 1983 Jun; 103(17-18):1397-9. PubMed ID: 6353660 [No Abstract] [Full Text] [Related]
34. Slow release salbutamol and Tedral in the treatment of reversible airways obstruction. Lal S; Bhalla KK; Davey AJ Postgrad Med J; 1971 Mar; 47():Suppl:89-92. PubMed ID: 4929401 [No Abstract] [Full Text] [Related]
35. [Controlled treatment with a retard theophylline preparation]. Wilke A; Iwainsky H; Kulpe K Prax Klin Pneumol; 1988 Jul; 42(7):603-5. PubMed ID: 3186668 [No Abstract] [Full Text] [Related]
36. [Theophylline in the therapy of non reversible airway obstruction]. Drigo R; Bevilacqua M; Franco R G Clin Med; 1987 Jan; 68(1):39-45. PubMed ID: 3301490 [No Abstract] [Full Text] [Related]